The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

Moderna, Baxter, and Pfizer are our top healthcare picks.

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Vaccine stocks have been under significant pressure since the FDA's top vaccine official resigned. Seeking Alpha analysts ...

Vaccines are a powerful tool of modern medicine, protecting you from diseases that once caused widespread suffering and death ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Boeing, General Electric, Moderna, Citigroup, Lockheed Martin, Celestica, and RTX are the seven Defense stocks to watch today, according to MarketBeat’s stock screener tool. Defense stocks are shares ...